vs

Side-by-side financial comparison of Atour Lifestyle Holdings Ltd (ATAT) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.

Atour Lifestyle Holdings Ltd is the larger business by last-quarter revenue ($789.6M vs $493.8M, roughly 1.6× Pediatrix Medical Group, Inc.). Atour Lifestyle Holdings Ltd runs the higher net margin — 17.6% vs 6.8%, a 10.8% gap on every dollar of revenue. On growth, Atour Lifestyle Holdings Ltd posted the faster year-over-year revenue change (252.5% vs -1.7%).

Atour Lifestyle Holdings Ltd is a leading China-based hospitality and lifestyle enterprise. It operates a wide portfolio of mid-to-premium hotel brands for business and leisure travelers, and offers complementary lifestyle retail products and experience services, catering primarily to middle-class consumers across domestic and selected overseas markets.

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

ATAT vs MD — Head-to-Head

Bigger by revenue
ATAT
ATAT
1.6× larger
ATAT
$789.6M
$493.8M
MD
Growing faster (revenue YoY)
ATAT
ATAT
+254.3% gap
ATAT
252.5%
-1.7%
MD
Higher net margin
ATAT
ATAT
10.8% more per $
ATAT
17.6%
6.8%
MD

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ATAT
ATAT
MD
MD
Revenue
$789.6M
$493.8M
Net Profit
$139.1M
$33.7M
Gross Margin
Operating Margin
22.5%
9.9%
Net Margin
17.6%
6.8%
Revenue YoY
252.5%
-1.7%
Net Profit YoY
322.2%
10.5%
EPS (diluted)
$0.33
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATAT
ATAT
MD
MD
Q4 25
$493.8M
Q3 25
$789.6M
$492.9M
Q2 25
$468.8M
Q1 25
$458.4M
Q4 24
$502.4M
Q3 24
$224.0M
$511.2M
Q2 24
$504.3M
Q1 24
$203.4M
$495.1M
Net Profit
ATAT
ATAT
MD
MD
Q4 25
$33.7M
Q3 25
$139.1M
$71.7M
Q2 25
$39.3M
Q1 25
$20.7M
Q4 24
$30.5M
Q3 24
$33.0M
$19.4M
Q2 24
$-153.0M
Q1 24
$35.6M
$4.0M
Operating Margin
ATAT
ATAT
MD
MD
Q4 25
9.9%
Q3 25
22.5%
13.8%
Q2 25
12.8%
Q1 25
7.0%
Q4 24
7.8%
Q3 24
14.7%
6.6%
Q2 24
-31.3%
Q1 24
22.1%
3.2%
Net Margin
ATAT
ATAT
MD
MD
Q4 25
6.8%
Q3 25
17.6%
14.5%
Q2 25
8.4%
Q1 25
4.5%
Q4 24
6.1%
Q3 24
14.7%
3.8%
Q2 24
-30.3%
Q1 24
17.5%
0.8%
EPS (diluted)
ATAT
ATAT
MD
MD
Q4 25
$0.40
Q3 25
$0.33
$0.84
Q2 25
$0.46
Q1 25
$0.24
Q4 24
$0.37
Q3 24
$0.08
$0.23
Q2 24
$-1.84
Q1 24
$0.09
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATAT
ATAT
MD
MD
Cash + ST InvestmentsLiquidity on hand
$669.2M
$375.2M
Total DebtLower is stronger
$570.5M
Stockholders' EquityBook value
$405.0M
$865.9M
Total Assets
$1.1B
$2.2B
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATAT
ATAT
MD
MD
Q4 25
$375.2M
Q3 25
$669.2M
$340.1M
Q2 25
$224.7M
Q1 25
$99.0M
Q4 24
$229.9M
Q3 24
$506.0M
$103.8M
Q2 24
$19.4M
Q1 24
$520.7M
$8.0M
Total Debt
ATAT
ATAT
MD
MD
Q4 25
$570.5M
Q3 25
$577.2M
Q2 25
$583.9M
Q1 25
$590.5M
Q4 24
$597.1M
Q3 24
Q2 24
Q1 24
$277.0K
Stockholders' Equity
ATAT
ATAT
MD
MD
Q4 25
$865.9M
Q3 25
$405.0M
$890.7M
Q2 25
$833.8M
Q1 25
$789.2M
Q4 24
$764.9M
Q3 24
$291.3M
$732.5M
Q2 24
$706.5M
Q1 24
$323.5M
$856.2M
Total Assets
ATAT
ATAT
MD
MD
Q4 25
$2.2B
Q3 25
$1.1B
$2.2B
Q2 25
$2.1B
Q1 25
$2.0B
Q4 24
$2.2B
Q3 24
$927.8M
$2.1B
Q2 24
$2.0B
Q1 24
$936.3M
$2.2B
Debt / Equity
ATAT
ATAT
MD
MD
Q4 25
0.66×
Q3 25
0.65×
Q2 25
0.70×
Q1 25
0.75×
Q4 24
0.78×
Q3 24
Q2 24
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATAT
ATAT
MD
MD
Operating Cash FlowLast quarter
$216.6M
$114.1M
Free Cash FlowOCF − Capex
$210.7M
FCF MarginFCF / Revenue
26.7%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
1.56×
3.39×
TTM Free Cash FlowTrailing 4 quarters
$359.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATAT
ATAT
MD
MD
Q4 25
$114.1M
Q3 25
$216.6M
$137.3M
Q2 25
$137.2M
Q1 25
$-117.5M
Q4 24
$133.0M
Q3 24
$84.8M
$91.8M
Q2 24
$107.0M
Q1 24
$19.8M
$-125.2M
Free Cash Flow
ATAT
ATAT
MD
MD
Q4 25
Q3 25
$210.7M
Q2 25
Q1 25
Q4 24
Q3 24
$83.3M
Q2 24
Q1 24
$18.1M
FCF Margin
ATAT
ATAT
MD
MD
Q4 25
Q3 25
26.7%
Q2 25
Q1 25
Q4 24
Q3 24
37.2%
Q2 24
Q1 24
8.9%
Capex Intensity
ATAT
ATAT
MD
MD
Q4 25
Q3 25
0.8%
Q2 25
Q1 25
Q4 24
Q3 24
0.7%
Q2 24
Q1 24
0.9%
Cash Conversion
ATAT
ATAT
MD
MD
Q4 25
3.39×
Q3 25
1.56×
1.91×
Q2 25
3.49×
Q1 25
-5.66×
Q4 24
4.36×
Q3 24
2.57×
4.72×
Q2 24
Q1 24
0.56×
-31.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATAT
ATAT

Segment breakdown not available.

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

Related Comparisons